OliX Pharmaceuticals, Inc (KOSDAQ:226950)
132,700
+7,700 (6.16%)
Dec 10, 2025, 3:30 PM KST
OliX Pharmaceuticals Revenue
OliX Pharmaceuticals had revenue of 2.91B KRW in the quarter ending September 30, 2025, with 1,002.56% growth. This brings the company's revenue in the last twelve months to 10.18B, down -36.91% year-over-year. In the year 2024, OliX Pharmaceuticals had annual revenue of 5.68B, down -66.73%.
Revenue (ttm)
10.18B
Revenue Growth
-36.91%
P/S Ratio
246.95
Revenue / Employee
n/a
Employees
n/a
Market Cap
2.51T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.68B | -11.39B | -66.73% |
| Dec 31, 2023 | 17.06B | 7.74B | 83.09% |
| Dec 31, 2022 | 9.32B | 5.65B | 153.66% |
| Dec 31, 2021 | 3.67B | 1.20B | 48.50% |
| Dec 31, 2020 | 2.47B | 1.34B | 118.90% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |